Literature DB >> 9052511

Anti-myenteric neuronal antibodies in patients with achalasia. A prospective study.

G N Verne1, J E Sallustio, E Y Eaker.   

Abstract

Achalasia is a motility disorder of the esophagus characterized by the loss of inhibitory neurons in the distal esophagus. Although idiopathic in nature, autoimmune mechanisms have been proposed, and we set out to determine the presence of myenteric neuronal antibodies. We prospectively studied 18 patients with well-characterized achalasia (by clinical, x-ray, and manometric evidence), nine with gastroesophageal reflux disease, and analyzed the sera from 22 disease-free controls. Using double-label, indirect immunofluorescence techniques, rat esophageal and intestinal sections were double-labeled with sera (dilutions of 1:50 to 1:400) from the three groups and with neurofilament antibody to localize neurons. Seven of 18 achalasia patients had sera that stained the majority of neurons within plexi in the esophageal and intestinal sections, including both NADPH diaphorase (nitric oxide synthase) -positive and -negative neurons. None of the gastroesophageal reflux patients or the controls showed staining. Neuronal antibodies in achalasia provide an attractive hypothesis to explain this diffuse, possibly immune-based disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052511     DOI: 10.1023/a:1018857617115

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  SCLERODERMA OF THE ESOPHAGUS. A CORRELATION OF HISTOLOGIC AND PHYSIOLOGIC FINDINGS.

Authors:  W L TREACY; A H BAGGENSTOSS; C H SLOCUMB; C F CODE
Journal:  Ann Intern Med       Date:  1963-09       Impact factor: 25.391

2.  Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease.

Authors:  S J Qualman; H M Haupt; P Yang; S R Hamilton
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

3.  Preliminary report of an association between measles virus and achalasia.

Authors:  D B Jones; J F Mayberry; J Rhodes; J Munro
Journal:  J Clin Pathol       Date:  1983-06       Impact factor: 3.411

4.  Paradoxical lower esophageal sphincter contraction induced by cholecystokinin-octapeptide in patients with achalasia.

Authors:  W J Dodds; J Dent; W J Hogan; G K Patel; J Toouli; R C Arndorfer
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

5.  Regulatory peptides in the lower esophageal sphincter of man.

Authors:  S Aggestrup; R Uddman; S L Jensen; F Sundler; O Schaffalitzky de Muckadell; J J Holst; R Håkanson; R Ekman; H R Sørensen
Journal:  Regul Pept       Date:  1985-03

Review 6.  Achalasia.

Authors:  J C Reynolds; H P Parkman
Journal:  Gastroenterol Clin North Am       Date:  1989-06       Impact factor: 3.806

7.  Achalasia of the cardia: pharmacology and histopathology of isolated cardiac sphincteric muscle from patients with and without achalasia.

Authors:  J J Misiewicz; S L Waller; P P Anthony; J W Gummer
Journal:  Q J Med       Date:  1969-01

8.  Significant DQw1 association in achalasia.

Authors:  R K Wong; C L Maydonovitch; S J Metz; J R Baker
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

9.  Lack of vasoactive intestinal polypeptide nerves in esophageal achalasia.

Authors:  S Aggestrup; R Uddman; F Sundler; J Fahrenkrug; R Håkanson; H R Sørensen; G Hambraeus
Journal:  Gastroenterology       Date:  1983-05       Impact factor: 22.682

10.  Gastroesophageal sphincter pressure and histological changes in distal esophagus in patients with achalasia of the esophagus.

Authors:  A Csendes; G Smok; I Braghetto; C Ramirez; N Velasco; A Henriquez
Journal:  Dig Dis Sci       Date:  1985-10       Impact factor: 3.199

View more
  26 in total

1.  Fever, ulcers and joint pain: an incidental finding of oesophageal dysmotility.

Authors:  Charles Anwuzia-Iwegbu; Asma Fikree; Nicola Tufton
Journal:  BMJ Case Rep       Date:  2013-08-29

2.  Achalasia and thyroid disease.

Authors:  Mohammad Hassan Emami; Mostafa Raisi; Jaleh Amini; Hamed Daghaghzadeh
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

3.  Enteric Nervous System: Neuropathic Gastrointestinal Motility.

Authors:  Jackie D Wood
Journal:  Dig Dis Sci       Date:  2016-07       Impact factor: 3.199

Review 4.  Pathophysiology of achalasia.

Authors:  I Hirano
Journal:  Curr Gastroenterol Rep       Date:  1999-06

5.  Serum from achalasia patients alters neurochemical coding in the myenteric plexus and nitric oxide mediated motor response in normal human fundus.

Authors:  S Bruley des Varannes; J Chevalier; S Pimont; J-C Le Neel; M Klotz; K-H Schafer; J-P Galmiche; M Neunlist
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

6.  Familial achalasia in children.

Authors:  Fawaz Chikh Torab; Moustafa Hamchou; Gabriel Ionescu; Ahmed H Al-Salem
Journal:  Pediatr Surg Int       Date:  2012-10-18       Impact factor: 1.827

7.  Neural autoantibody profile of primary achalasia.

Authors:  Robert E Kraichely; Gianrico Farrugia; Sean J Pittock; Donald O Castell; Vanda A Lennon
Journal:  Dig Dis Sci       Date:  2009-06-05       Impact factor: 3.199

8.  Anti-ganglionic AChR antibodies in Japanese patients with motility disorders.

Authors:  Akihiro Mukaino; Hitomi Minami; Hajime Isomoto; Hitomi Hamamoto; Eikichi Ihara; Yasuhiro Maeda; Osamu Higuchi; Tohru Okanishi; Yohei Kokudo; Kazushi Deguchi; Fumisato Sasaki; Toshihito Ueki; Ken-Ya Murata; Takeshi Yoshida; Mistuyo Kinjo; Yoshihiro Ogawa; Akio Ido; Hidenori Matsuo; Kazuhiko Nakao; Shunya Nakane
Journal:  J Gastroenterol       Date:  2018-05-15       Impact factor: 7.527

Review 9.  [Treatment of achalasia].

Authors:  Enrico P Cosentini; Etienne Wenzl; Raimund Jakesz
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

10.  Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease.

Authors:  P L Moses; L M Ellis; M R Anees; W Ho; R I Rothstein; J B Meddings; K A Sharkey; G M Mawe
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.